Signal Transduction and Targeted Therapy

Signal Transduction and Targeted Therapy

主编介绍

Co-Editors-In-Chief

Prof. Carlo M. Croce, Institute of Genetics, The Ohio State University, Columbus, Ohio, USA
Prof. Carlo M. Croce (M.D.) was born in 1944. He received his B.S. and M.D. degrees from University of Rome in 1967 and 1969, respectively. In 1970, he joined the Wistar Institute of Anatomy and Biology as an associate scientist. He became a faculty member in 1971, and was promoted to professor in 1976 and associate director in 1980. In 1991, Dr. Croce was recruited as director of Kimmel Cancer Institute/Kimmel Cancer Center, Thomas Jefferson University. In 2004, Dr. Croce became John W. Wolfe Chair in Human Cancer Genetics, Chairman of the Department of Molecular Virology, Immunology and Medical Genetics, and Director of the Institute of Genetics, The Ohio State University. He has published more than 1000 papers in international journals including Science, NatureCellNew Engl J MedJAMA, and Cancer Cell. His research has yielded 62 issued U.S. patents. Dr. Croce is a member of the American Academy of Arts and Sciences, the American Association for the Advancement of Science, The National Academy of Sciences, the Institute of Medicine, and AACR Academy. He was an Editor-in-Chief of Cancer Research (1990-1999).

Prof. Kang Zhang, Institute for Genomic Medicine, University of California San Diego, USA
Dr. Zhang obtained his M.D. with Magna Cum Laude honors from the Harvard Medical School and MIT joint program and his Ph.D. in genetics from Harvard University. He completed his residency in ophthalmology at Wilmer Eye Institute at Johns Hopkins University and his retina fellowship at University of Utah. He was a faculty member at Johns Hopkins University, Cleveland Clinic Foundation, and the University of Utah. Dr. Zhang is currently the founding director of the Institute for Genomic Medicine, co-director of the BioMaterials and Tissue Engineering Center at the Institute of Engineering in Medicine, Professor of Ophthalmology and Genetics, and Chief of Ophthalmic Genetics at the University of California San Diego. Dr. Zhang’s clinical and research spans novel disease gene targets and treatments, gene- and stem cell-based therapies, 3D bioprinting and tissue engineering, drug discovery and delivery, aging and epigenetics, and clinical trials. He has published more than 150 papers in international journals including Nature, ScienceCellPNASNew Engl J Med, and Mol Cell. He has numerous grants from the National Institutes of Health and other foundations. His discovery that HTRA1 is a major susceptibility gene for age-related macular degeneration is listed as one of “top-ten breakthroughs in 2006” by Science.

Prof. Yu-Quan Wei, State Key Laboratory of Biotherapy/Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University, China 

Yu-quan Wei, Ph.D., Professor and Director of National/State Key Laboratory of Biotherapy and Clinical Cancer Center, West China Hospital, West China Medical School, Sichuan University, Chengdu. He was educated at West China University of Medical Sciences for a bachelor's degree in Medicine and a Master's Degree in Medicine, and educated at Kyoto University in Japan for Doctoral Degree. His major research interests include: targeted therapy, signal transduction, gene and cell therapy, and cancer vaccines. He has published more than 300 papers in international journals including Nat MedNat CommunPNASBloodCancer ResClinic Cancer ResJ Immunol, and J Biol Chem, etc. He was selected as an academician of Chinese Academy of Sciences in 2003. He is now the vice president of Sichuan University, President of China Medicinal Biotech Association, Vice President of Chinese Association of Medicine. He has served as an associate editor of Human Gene Therapy and Editorial Board Member of several International Journals.